NEW YORK, Aug. 5, 2002 (PRIMEZONE) -- Dr. John Maraganore, Senior VP of Strategic Product Development for Millennium Pharmaceuticals, Inc. (Nasdaq:MLNM), opens the interview with the cornerstones of Millennium's strategy for establishing itself as a sector leader in various areas. He then addresses the concerns that the industry has been facing and the causes behind recent investor weakness. Moving on the R&D we discuss the large budget that the company has devoted to this area and the results of this.
Looking at the Company's upcoming Cancer drug, VELCADE, Dr. Maraganore gives his outlook on when we might expect to see it in the market and the progress that we can extrapolate from the phase 3 trials.
Mergers and Acquisitions have been an important aspect for Millennium's business building process and we examine the conditions that have assisted in this. We expand this discussion to look at the current market conditions and what we might hope to see from Millennium in the short term. We then look into Thermogenics and explore various examples of this technology.
The interview is closed with an explanation of the factors that are considered and the manner in which they are applied when deciding which drugs to invest in and the areas chosen for discovery research.
The interview can be heard on www.wallst.net
About Millennium Pharmaceuticals Inc.
Millennium Pharmaceuticals Inc. is a biopharmaceutical company focused on applying its comprehensive and integrated science and technology platform to discover and accelerate the development of drugs and predictive medicine products. These drugs and products may enable physicians to more closely customize medical treatment by combining knowledge of the genetic basis for disease and the genetic characteristics of a patient. Millennium primarily focuses its research and development and commercialization activities in four key disease areas: cardiovascular, oncology, inflammatory and metabolic.
About WallSt.net
The Wall St. Network (www.wallst.net) is a multimedia provider of original, insightful, commentary and news from North America's leading companies. Giving a direct link to the management of today's fastest growing companies through encompassing executive interviews and Sector Seminars.